Humacyte (NASDAQ:HUMA) Stock Rating Raised to "Sell" at Wall Street Zen

Key Points

• Wall Street Zen moved Humacyte to a “Sell” rating, while analyst sentiment overall remains “Moderate Buy”: six analysts rate it Buy, one Hold and one Sell, with a $4.48 consensus price target.
• Humacyte reported a quarterly loss of $0.16 per share, worse than the $0.11 loss analysts expected; revenue of $0.41 million also missed the $1.04 million estimate.
• Shares opened at $0.56, within a 12-month range of $0.34 to $1.52. The company’s latest reported financial results point to continued losses, and analysts forecast a $0.38 loss per share for the current year.

Humacyte (NASDAQ:HUMA - Get Free Report) was upgraded by analysts at Wall Street Zen to a "sell" rating in a research note issued to investors on Saturday, Wall Street Zen reports.

HUMA has been the subject of a number of other reports. BTIG Research reissued a "buy" rating and issued a $2.00 target price on shares of Humacyte in a research note on Tuesday. Barclays raised their price target on Humacyte from $0.50 to $0.60 and gave the stock an "equal weight" rating in a research report on Wednesday. Williams Trading set a $1.00 price objective on Humacyte in a report on Friday, October 16th. HC Wainwright reiterated a "buy" rating on shares of Humacyte in a report on Friday, October 16th. Finally, Benchmark decreased their price objective on Humacyte from $2.00 to $1.00 and set a "speculative buy" rating for the company in a research report on Thursday, August 13th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Humacyte presently has an average rating of "Moderate Buy" and a consensus price target of $4.48.

Humacyte Price Performance

Shares of NASDAQ HUMA opened at $0.56 on Friday. The company's fifty day moving average is $0.49 and its 200-day moving average is $0.78. Humacyte has a twelve month low of $0.34 and a twelve month high of $1.52. The company has a debt-to-equity ratio of 3.65, a current ratio of 3.34 and a quick ratio of 5.74.

Humacyte (NASDAQ:HUMA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.05). The firm had revenue of $0.41 million during the quarter, compared to analyst estimates of $1.04 million. Humacyte had a negative net margin of 3,955.05% and a negative return on equity of 612.88%. On average, equities analysts predict that Humacyte will post -0.38 earnings per share for the current year.

Hedge Funds Weigh In On Humacyte

Hedge funds have recently made changes to their positions in the business. Alyeska Investment Group L.P. acquired a new stake in shares of Humacyte in the second quarter valued at approximately $4,700,000. BlackRock Inc. bought a new stake in shares of Humacyte in the second quarter worth $3,777,000. Marshall Wace LLP boosted its holdings in Humacyte by 1,548.0% during the third quarter. Marshall Wace LLP now owns 2,996,553 shares of the company's stock worth $1,558,000 after purchasing an additional 2,814,722 shares during the last quarter. GSA Capital Partners LLP acquired a new position in Humacyte during the second quarter worth $785,000. Finally, Private Advisor Group LLC acquired a new position in Humacyte during the third quarter worth $491,000. 44.71% of the stock is owned by institutional investors.

Latest Humacyte News

Here's some of the latest news about HUMA:

• Positive Sentiment: HC Wainwright raised its estimated loss per share for FY2026 to $0.39 from $0.46, and narrowed its projected losses for Q4 2026 and Q1 2027. The firm maintained its Buy rating.
• Positive Sentiment: StoneX reiterated its Speculative Buy rating, while a separate roundup highlighted Humacyte among healthcare stocks with bullish analyst views. StoneX Reiterates Speculative Buy Rating on Humacyte Analysts Are Bullish on These Healthcare Stocks
• Negative Sentiment: HC Wainwright trimmed estimates for FY2027 and FY2028, and lowered projected Q3 and Q4 2027 results. It now expects a $0.31-per-share loss in FY2027 and a $0.11 loss in FY2028, signaling a slower path to profitability than previously forecast.

Humacyte Company Profile

Humacyte, Inc. is a biotechnology company developing bioengineered human tissues for vascular repair and other medical applications. Its technology uses human vascular cells to create vessels that are processed to remove the cells, leaving an acellular structure designed for implantation. The company's lead product, Symvess, is an acellular tissue-engineered vessel for treating extremity arterial injuries in adults when a patient's own vein cannot be used for surgical revascularization. The U.S. Food and Drug Administration approved Symvess in December 2024.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.